Dr. Storandt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2024 - 2027
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2021 - 2024
University of North Dakota School of Medicine and Health SciencesClass of 2021
Certifications & Licensure
MN State Medical License 2022 - 2025
Publications & Presentations
PubMed
- Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.Michael H Storandt, Tyler J Zemla, Kanchi Patell, Nikolas Naleid, Jennifer J Gile
The Oncologist. 2024-11-04 - Frequency of Common and UncommonAlterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies.Amit Mahipal, Michael H Storandt, Emily A Teslow, Ellen Jaeger, Melissa C Stoppler
Cancers. 2024-05-10 - 1 citationsMetabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.Kanchi Patell, Veronica Lee Mears, Michael H Storandt, Amit Mahipal
Expert Opinion on Drug Metabolism & Toxicology. 2024-04-01
Press Mentions
Mayo Clinic Comprehensive Cancer Center to Highlight Key Studies at ASCO 2024May 31st, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
